pancreatic cancer with liver metastasis
Conditions
Interventions
Testt Group:Multi-modal ablation combined with the AG regimen and sintilimab
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years, regardless of gender; 2. Patients with newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or meeting clinical diagnostic criteria, without metastasis to other organs except the liver; 3. The number of liver metastatic lesions 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously received radiotherapy, surgery, chemotherapy, or investigational treatment for metastatic disease (patients who have previously received gemcitabine or fluorouracil adjuvant chemotherapy are eligible for enrollment if the treatment has been completed and the interval from the end of treatment to the start of the first study treatment exceeds 6 months); 2. Patients who have participated in other clinical trials in the past 4 weeks; 3. Diffuse liver metastasis; 4. Liver function classified as Child-Pugh Class C, or severe jaundice (especially obstructive jaundice); patients are eligible for enrollment if bilirubin is significantly reduced and liver function, body temperature, and blood parameters return to normal after jaundice reduction treatment; 5. Severe hepatic or renal insufficiency and coagulation disorders (serum creatinine > 176.8 µmol/L or creatinine clearance 18 seconds; prothrombin activity < 40%, and these conditions cannot be corrected); 6. Uncontrolled comorbidities, including poorly controlled hypertension or diabetes, persistent active infection, or mental illness or social conditions that may affect the subject’s compliance with the study; 7. Refractory massive ascites, pleural effusion, or cachexia; 8. Pregnancy or lactation; 9. Other factors that, in the investigator’s opinion, make the subject unsuitable for enrollment or affect their participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Ablation Rate;Progression-Free Survival;Overall Survival;Immune Indicator Changes;Adverse Event; | — |
Countries
China
Contacts
Public ContactXiao Hu
The Affiliated Hospital of Qingdao University
Outcome results
None listed